Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)

Key Points

• To evaluate the long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world setting.
• Conducted a multicenter medical chart review over 2.5 years.
• Analyzed data from patients treated with satralizumab in Japan.
• Focused on safety and effectiveness outcomes.
• Satralizumab demonstrated a favorable safety profile.
• Long-term analysis indicates effective management of neuromyelitis optica spectrum disorder.